Breast Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Breast Cancer, including details on symptoms, genetics, screening, treatment, information.

Volume 5 (2008), Issue 4 (April)

1. BRCA1 and stem cells: tumour typecasting.
   Nat Cell Biol, 10(4): 377-9. [Abstract] [Full-text]
2. Influence of ABCB1 and ABCG2 polymorphisms on doxorubicin disposition in Asian breast cancer patients.
   Cancer Sci, 99(4): 816-23. [Abstract] [Full-text]
3. Management of the axilla in women with breast cancer: current clinical practice and a new selective targeted approach.
   Ann Surg Oncol, 15(5): 1282-96. [Abstract] [Full-text]
4. Sentinel lymph node biopsy after neoadjuvant chemotherapy is accurate in breast cancer patients with a clinically negative axillary nodal status at presentation.
   Ann Surg Oncol, 15(5): 1316-21. [Abstract] [Full-text]
5. Predictors of re-excision among women undergoing breast-conserving surgery for cancer.
   Ann Surg Oncol, 15(5): 1297-303. [Abstract] [Full-text]
6. Technical considerations in nipple-sparing mastectomy: 82 consecutive cases without necrosis.
   Ann Surg Oncol, 15(5): 1341-7. [Abstract] [Full-text]
7. The microanatomic location of metastatic breast cancer in sentinel lymph nodes predicts nonsentinel lymph node involvement.
   Ann Surg Oncol, 15(5): 1309-15. [Abstract] [Full-text]
8. The superficial margin of the skin-sparing mastectomy for breast carcinoma: factors predicting involvement and efficacy of additional margin sampling.
   Ann Surg Oncol, 15(5): 1330-40. [Abstract] [Full-text]
9. Outcomes of locoregional recurrence after surgical chest wall resection and reconstruction for breast cancer.
   Ann Surg Oncol, 15(5): 1322-9. [Abstract] [Full-text]
10. When sentinel lymph node is intramammary.
    Ann Surg Oncol, 15(5): 1304-8. [Abstract] [Full-text]
11. Disparities and trends in sentinel lymph node biopsy among early-stage breast cancer patients (1998-2005).
    J Natl Cancer Inst, 100(7): 462-74. [Abstract] [Full-text]
12. Increased risk of recurrence after hormone replacement therapy in breast cancer survivors.
    J Natl Cancer Inst, 100(7): 475-82. [Abstract] [Full-text]
13. MCF7 side population cells with characteristics of cancer stem/progenitor cells express the tumor antigen MUC1.
    Cancer Res, 68(7): 2419-26. [Abstract] [Full-text]
14. The nucleolin targeting aptamer AS1411 destabilizes Bcl-2 messenger RNA in human breast cancer cells.
    Cancer Res, 68(7): 2358-65. [Abstract] [Full-text]
15. The role of amphiregulin in exemestane-resistant breast cancer cells: evidence of an autocrine loop.
    Cancer Res, 68(7): 2259-65. [Abstract] [Full-text]
16. Six1 overexpression in mammary cells induces genomic instability and is sufficient for malignant transformation.
    Cancer Res, 68(7): 2204-13. [Abstract] [Full-text]
17. Attenuation of junctional adhesion molecule-A is a contributing factor for breast cancer cell invasion.
    Cancer Res, 68(7): 2194-203. [Abstract] [Full-text]
18. Hypoxia down-regulates CCAAT/enhancer binding protein-alpha expression in breast cancer cells.
    Cancer Res, 68(7): 2158-65. [Abstract] [Full-text]
19. Frequency of the CHEK2 1100delC mutation among women with breast cancer: an international study.
    Cancer Res, 68(7): 2154-7. [Abstract] [Full-text]
20. Bisphenol A induces a profile of tumor aggressiveness in high-risk cells from breast cancer patients.
    Cancer Res, 68(7): 2076-80. [Abstract] [Full-text]
21. Oncogene cooperation in tumor maintenance and tumor recurrence in mouse mammary tumors induced by Myc and mutant Kras.
    Proc Natl Acad Sci U S A, 105(13): 5242-7. [Abstract] [Full-text]
22. Estrogen-biosynthesis gene CYP17 and its interactions with reproductive, hormonal and lifestyle factors in breast cancer risk: results from the Long Island Breast Cancer Study Project.
    Carcinogenesis, 29(4): 766-71. [Abstract] [Full-text]
23. MDM2 SNP309 G allele increases risk but the T allele is associated with earlier onset age of sporadic breast cancers in the Chinese population.
    Carcinogenesis, 29(4): 754-61. [Abstract] [Full-text]
24. 15-Deoxy-Delta12,14-prostaglandin J2 induces COX-2 expression through Akt-driven AP-1 activation in human breast cancer cells: a potential role of ROS.
    Carcinogenesis, 29(4): 688-95. [Abstract] [Full-text]
25. Curcumin downregulates the inflammatory cytokines CXCL1 and -2 in breast cancer cells via NFkappaB.
    Carcinogenesis, 29(4): 779-89. [Abstract] [Full-text]
26. In situ monitoring of 3D in vitro cell aggregation using an optical imaging system.
    Biotechnol Bioeng, 100(1): 159-67. [Abstract] [Full-text]
27. Choices in cancer treatment: a qualitative study of the older women's (>70 years) perspective.
    Psychooncology, 17(4): 410-6. [Abstract] [Full-text]
28. Chemotherapy-induced alopecia and effects on quality of life among women with breast cancer: a literature review.
    Psychooncology, 17(4): 317-28. [Abstract] [Full-text]
29. Latina a Latina: developing a breast cancer decision support intervention.
    Psychooncology, 17(4): 383-91. [Abstract] [Full-text]
30. Daintain/AIF-1 promotes breast cancer proliferation via activation of the NF-kappaB/cyclin D1 pathway and facilitates tumor growth.
    Cancer Sci, 99(5): 952-7. [Abstract] [Full-text]
31. Functional analysis of individual cells and microenvironment of breast cancer-draining lymph nodes.
    Cancer Sci, 99(5): 936-45. [Abstract] [Full-text]
32. Impact of CYP2D6*10 on recurrence-free survival in breast cancer patients receiving adjuvant tamoxifen therapy.
    Cancer Sci, 99(5): 995-9. [Abstract] [Full-text]
33. Intra-operative rapid diagnostic method based on CK19 mRNA expression for the detection of lymph node metastases in breast cancer.
    Int J Cancer, 122(11): 2562-7. [Abstract] [Full-text]
34. V gamma 9 V delta 2 T cell cytotoxicity against tumor cells is enhanced by monoclonal antibody drugs--rituximab and trastuzumab.
    Int J Cancer, 122(11): 2526-34. [Abstract] [Full-text]
35. Tenascin-W, a new marker of cancer stroma, is elevated in sera of colon and breast cancer patients.
    Int J Cancer, 122(11): 2454-61. [Abstract] [Full-text]
36. Breast cancer-associated mutations in metalloprotease disintegrin ADAM12 interfere with the intracellular trafficking and processing of the protein.
    Int J Cancer, 122(11): 2634-40. [Abstract] [Full-text]
37. Breast cancer metastases are molecularly distinct from their primary tumors.
    Oncogene, 27(15): 2148-58. [Abstract] [Full-text]
38. A potential dichotomous role of ATF3, an adaptive-response gene, in cancer development.
    Oncogene, 27(15): 2118-27. [Abstract] [Full-text]
39. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer.
    JAMA, 299(13): 1574-87. [Abstract] [Full-text]
40. Neoadjuvant chemotherapy in invasive breast cancer results in a lower axillary lymph node count.
    J Am Coll Surg, 206(4): 704-8. [Abstract] [Full-text]
41. Sentinel lymph node biopsy is successful and accurate in male breast carcinoma.
    J Am Coll Surg, 206(4): 616-21. [Abstract] [Full-text]
42. Do variations in provider discussions explain socioeconomic disparities in postmastectomy breast reconstruction?
    J Am Coll Surg, 206(4): 605-15. [Abstract] [Full-text]
43. "Coming to grips" with chemotherapy-induced premature menopause.
    Health Care Women Int, 29(4): 384-99. [Abstract] [Full-text]
44. High MMP-1 mRNA expression is a risk factor for disease-free and overall survivals in patients with invasive breast carcinoma.
    J Surg Res, 146(1): 104-9. [Abstract] [Full-text]
45. TGFbeta primes breast tumors for lung metastasis seeding through angiopoietin-like 4.
    Cell, 133(1): 66-77. [Abstract] [Full-text]
46. Metastatic disease to the pancreas and spleen.
    Semin Oncol, 35(2): 160-71. [Abstract] [Full-text]
47. Impact of treatment and socioeconomic status on racial disparities in survival among older women with breast cancer.
    Am J Clin Oncol, 31(2): 125-32. [Abstract] [Full-text]
48. High-dose chemotherapy for patients with high-risk breast cancer: a clinical and economic assessment using a quality-adjusted survival analysis.
    Am J Clin Oncol, 31(2): 117-24. [Abstract] [Full-text]
49. Competing causes of death for women with breast cancer and change over time from 1975 to 2003.
    Am J Clin Oncol, 31(2): 105-16. [Abstract] [Full-text]
50. Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers.
    Am J Hum Genet, 82(4): 937-48. [Abstract] [Full-text]
51. High-resolution genomic and expression analyses of copy number alterations in breast tumors.
    Genes Chromosomes Cancer, 47(6): 530-42. [Abstract] [Full-text]
52. DNA copy number alterations and expression of relevant genes in triple-negative breast cancer.
    Genes Chromosomes Cancer, 47(6): 490-9. [Abstract] [Full-text]
53. Phase I study of a novel capecitabine schedule based on the Norton-Simon mathematical model in patients with metastatic breast cancer.
    J Clin Oncol, 26(11): 1797-802. [Abstract] [Full-text]
54. Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane.
    J Clin Oncol, 26(11): 1810-6. [Abstract] [Full-text]
55. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer.
    J Clin Oncol, 26(11): 1789-96. [Abstract] [Full-text]
56. Occult axillary node metastases in breast cancer are prognostically significant: results in 368 node-negative patients with 20-year follow-up.
    J Clin Oncol, 26(11): 1803-9. [Abstract] [Full-text]
57. p53 regulates FAK expression in human tumor cells.
    Mol Carcinog, 47(5): 373-82. [Abstract] [Full-text]
58. The DNA damage signalling kinase ATM is aberrantly reduced or lost in BRCA1/BRCA2-deficient and ER/PR/ERBB2-triple-negative breast cancer.
    Oncogene, 27(17): 2501-6. [Abstract] [Full-text]
59. Correlates of patient satisfaction and provider trust after breast-conserving surgery.
    Cancer, 112(8): 1679-87. [Abstract] [Full-text]
60. Moderators of the effects of exercise training in breast cancer patients receiving chemotherapy: a randomized controlled trial.
    Cancer, 112(8): 1845-53. [Abstract] [Full-text]
61. Distinction between isolated tumor cells and micrometastases in breast cancer: is it reliable and useful?
    Cancer, 112(8): 1672-8. [Abstract] [Full-text]
62. Evaluation of paired-end sequencing strategies for detection of genome rearrangements in cancer.
    PLoS Comput Biol, 4(4): e1000051. [Abstract] [Full-text]
63. Clinicopathological and prognostic relevance of uptake level using 18F-fluorodeoxyglucose positron emission tomography/computed tomography fusion imaging (18F-FDG PET/CT) in primary breast cancer.
    Jpn J Clin Oncol, 38(4): 250-8. [Abstract] [Full-text]
64. Clinical proteomics and breast cancer: strategies for diagnostic and therapeutic biomarker discovery.
    Future Oncol, 4(2): 271-87. [Abstract] [Full-text]
65. Meta-analysis of sentinel node biopsy in ductal carcinoma in situ of the breast.
    Br J Surg, 95(5): 547-54. [Abstract] [Full-text]
66. Free circulating mRNA in plasma from breast cancer patients and clinical outcome.
    Cancer Lett, 263(2): 312-20. [Abstract] [Full-text]
67. Molecular signature detection of circulating tumor cells using a panel of selected genes.
    Cancer Lett, 263(2): 267-79. [Abstract] [Full-text]
68. BARD1 regulates BRCA1-mediated transactivation of the p21WAF1/CIP1 and Gadd45 promoters.
    Cancer Lett, 263(2): 189-96. [Abstract] [Full-text]
69. Selective apoptosis of breast cancer cells by siRNA targeting of BORIS.
    Biochem Biophys Res Commun, 370(1): 109-12. [Abstract] [Full-text]
70. Methylation of the DFNA5 increases risk of lymph node metastasis in human breast cancer.
    Biochem Biophys Res Commun, 370(1): 38-43. [Abstract] [Full-text]
71. Poland's syndrome complicated with breast cancer: mammographic, ultrasonographic, and computed tomographic findings.
    Acta Radiol, 49(4): 387-90. [Abstract] [Full-text]
72. Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial.
    J Natl Cancer Inst, 100(8): 542-51. [Abstract] [Full-text]
73. Intensified neoadjuvant chemotherapy in early-responding breast cancer: phase III randomized GeparTrio study.
    J Natl Cancer Inst, 100(8): 552-62. [Abstract] [Full-text]
74. Dopamine increases the efficacy of anticancer drugs in breast and colon cancer preclinical models.
    Clin Cancer Res, 14(8): 2502-10. [Abstract] [Full-text]
75. Pathologic complete response to neoadjuvant chemotherapy of breast carcinoma is associated with the disappearance of tumor-infiltrating foxp3+ regulatory T cells.
    Clin Cancer Res, 14(8): 2413-20. [Abstract] [Full-text]
76. Vascularization in primary breast carcinomas: its prognostic significance and relationship with tumor cell dissemination.
    Clin Cancer Res, 14(8): 2341-50. [Abstract] [Full-text]
77. DNMT3A and DNMT3B mediate autocrine hGH repression of plakoglobin gene transcription and consequent phenotypic conversion of mammary carcinoma cells.
    Oncogene, 27(18): 2602-12. [Abstract] [Full-text]
78. Weekly paclitaxel in the adjuvant treatment of breast cancer.
    N Engl J Med, 358(16): 1663-71. [Abstract] [Full-text]
79. Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer.
    J Clin Oncol, 26(12): 1993-9. [Abstract] [Full-text]
80. Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer.
    J Clin Oncol, 26(12): 1987-92. [Abstract] [Full-text]
81. Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer.
    J Clin Oncol, 26(12): 1980-6. [Abstract] [Full-text]
82. Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen.
    J Clin Oncol, 26(12): 1948-55. [Abstract] [Full-text]
83. Efficacy, toxicity, and quality of life in older women with early-stage breast cancer treated with letrozole or placebo after 5 years of tamoxifen: NCIC CTG intergroup trial MA.17.
    J Clin Oncol, 26(12): 1956-64. [Abstract] [Full-text]
84. Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast And Bowel Project B-33 trial.
    J Clin Oncol, 26(12): 1965-71. [Abstract] [Full-text]
85. Letrozole compared with tamoxifen for elderly patients with endocrine-responsive early breast cancer: the BIG 1-98 trial.
    J Clin Oncol, 26(12): 1972-9. [Abstract] [Full-text]
86. Histone deacetylase inhibitor SAHA induces ERalpha degradation in breast cancer MCF-7 cells by CHIP-mediated ubiquitin pathway and inhibits survival signaling.
    Biochem Pharmacol, 75(9): 1697-705. [Abstract] [Full-text]
87. Allelic imbalance in BRCA1 and BRCA2 gene expression is associated with an increased breast cancer risk.
    Hum Mol Genet, 17(9): 1336-48. [Abstract] [Full-text]
88. Estrogen receptor genotypes, menopausal status, and the lipid effects of tamoxifen.
    Clin Pharmacol Ther, 83(5): 702-10. [Abstract] [Full-text]
89. Incidence and outcomes of contralateral breast cancers.
    Am J Surg, 195(5): 645-50; discussion 650. [Abstract] [Full-text]
90. Primary tumor location impacts breast cancer survival.
    Am J Surg, 195(5): 641-4. [Abstract] [Full-text]
91. Targeted breast cancer screening in women younger than 40: results from a statewide program.
    Am J Surg, 195(5): 626-30; discussion 630. [Abstract] [Full-text]
92. Standardized evaluation of regional and institutional breast cancer outcomes.
    Am J Surg, 195(5): 636-40; discussion 640. [Abstract] [Full-text]
93. Real-world application of breast-specific gamma imaging, initial experience at a community breast center and its potential impact on clinical care.
    Am J Surg, 195(5): 631-5; discussion 635. [Abstract] [Full-text]
94. Prevention of futile sentinel node procedures in breast cancer: ultrasonography of the axilla and fine-needle aspiration cytology are obligatory.
    Eur J Surg Oncol, 34(5): 497-500. [Abstract] [Full-text]
95. Presence of mature DC-Lamp+ dendritic cells in sentinel and non-sentinel lymph nodes of breast cancer patients.
    Eur J Surg Oncol, 34(5): 514-8. [Abstract] [Full-text]
96. Morbidity comparison of sentinel lymph node biopsy versus conventional axillary lymph node dissection for breast cancer patients: results of the sentinella-GIVOM Italian randomised clinical trial.
    Eur J Surg Oncol, 34(5): 508-13. [Abstract] [Full-text]
97. Stage of breast cancers found during the surveillance of women with a familial or hereditary risk.
    Eur J Surg Oncol, 34(5): 501-7. [Abstract] [Full-text]
98. Detection of human papillomavirus DNA by DNA chip in breast carcinomas of Korean women.
    Tumour Biol, 28(6): 327-32. [Abstract] [Full-text]
99. BRCA1 and BRCA2 germline mutations in Malaysian women with early-onset breast cancer without a family history.
    PLoS ONE, 3(4): e2024. [Abstract] [Full-text]
100. Damaged DNA binding protein 2 plays a role in breast cancer cell growth.
     PLoS ONE, 3(4): e2002. [Abstract] [Full-text]
101. Autologous and alloplastic breast reconstruction--overview of techniques, indications and results.
     Gynakol Geburtshilfliche Rundsch, 48(2): 68-75. [Abstract] [Full-text]
102. Breast-conserving treatment of breast cancer--oncological and reconstructive aspects.
     Gynakol Geburtshilfliche Rundsch, 48(2): 56-62. [Abstract] [Full-text]
103. Metastatic breast carcinoma identified in a uterine leiomyosarcoma.
     Pathol Int, 58(5): 317-21. [Abstract] [Full-text]
104. CD109 expression in basal-like breast carcinoma.
     Pathol Int, 58(5): 288-94. [Abstract] [Full-text]
105. Dinucleotide repeat polymorphisms of RAD51, BRCA1, BRCA2 gene regions in breast cancer.
     Pathol Int, 58(5): 275-81. [Abstract] [Full-text]
106. Beauty and the beast: management of breast cancer after plastic surgery.
     Ann Surg, 247(4): 680-6. [Abstract] [Full-text]
107. Genomic analysis of the HER2/TOP2A amplicon in breast cancer and breast cancer cell lines.
     Lab Invest, 88(5): 491-503. [Abstract] [Full-text]
108. Synthesis and structure-activity relationship studies on tryprostatin A, an inhibitor of breast cancer resistance protein.
     Bioorg Med Chem, 16(8): 4626-51. [Abstract] [Full-text]
109. Sentinel node positive breast cancer patients who do not undergo axillary dissection: are they different?
     Surgery, 143(5): 641-7. [Abstract] [Full-text]
110. Evidence from nonrandomized studies: a case study on the estimation of causal effects.
     Am J Epidemiol, 167(9): 1120-9. [Abstract] [Full-text]
111. Aberrant expression of E-cadherin in lobular carcinomas of the breast.
     Am J Surg Pathol, 32(5): 773-83. [Abstract] [Full-text]
112. Coincidence of mammary and sentinel lymph node papilloma.
     Am J Surg Pathol, 32(5): 784-92. [Abstract] [Full-text]
113. Obesity and screening for breast, cervical, and colorectal cancer in women: a review.
     Cancer, 112(9): 1892-904. [Abstract] [Full-text]
114. BRCA1 regulates caveolin-1 expression and inhibits cell invasiveness.
     Biochem Biophys Res Commun, 370(2): 201-6. [Abstract] [Full-text]
115. Role of resection margins in patients treated with breast conservation surgery.
     Cancer, 112(9): 1923-31. [Abstract] [Full-text]
116. Basal carcinoma of the breast revisited: an old entity with new interpretations.
     J Clin Pathol, 61(5): 553-60. [Abstract] [Full-text]
117. Establishing treatment benchmarks for mammography-screened breast cancer population based on a review of evidence-based clinical guidelines.
     Cancer, 112(9): 1912-22. [Abstract] [Full-text]
118. Prognostic significance of HER-2 status in women with inflammatory breast cancer.
     Cancer, 112(9): 1905-11. [Abstract] [Full-text]
119. Reduction of E-cadherin expression is associated with non-lobular breast carcinomas of basal-like and triple negative phenotype.
     J Clin Pathol, 61(5): 615-20. [Abstract] [Full-text]
120. Bone marrow micrometastasis in breast cancer: review of detection methods, prognostic impact and biological issues.
     J Clin Pathol, 61(5): 570-6. [Abstract] [Full-text]
121. No evidence of clonal somatic genetic alterations in cancer-associated fibroblasts from human breast and ovarian carcinomas.
     Nat Genet, 40(5): 650-5. [Abstract] [Full-text]
122. Nomogram for the prediction of having four or more involved nodes for sentinel lymph node-positive breast cancer.
     J Clin Oncol, 26(13): 2093-8. [Abstract] [Full-text]
123. Bromodomain 4 activation predicts breast cancer survival.
     Proc Natl Acad Sci U S A, 105(17): 6380-5. [Abstract] [Full-text]
124. Capecitabine and vinorelbine as first-line treatment in elderly patients (> or =65 years) with metastatic breast cancer. A phase II trial (SAKK 25/99).
     Oncology, 73(3): 228-37. [Abstract] [Full-text]
125. Phase II trial of pegylated liposomal doxorubicin-cyclophosphamide combination as first-line chemotherapy in older metastatic breast cancer patients.
     Oncology, 73(3): 210-4. [Abstract] [Full-text]
126. A multicenter randomized trial of breast intensity-modulated radiation therapy to reduce acute radiation dermatitis.
     J Clin Oncol, 26(13): 2085-92. [Abstract] [Full-text]
127. Estrogen-mediated downregulation of CD24 in breast cancer cells.
     Int J Cancer, 123(1): 66-72. [Abstract] [Full-text]
128. How basal are triple-negative breast cancers?
     Int J Cancer, 123(1): 236-40. [Abstract] [Full-text]
129. Expression and splicing of the unfolded protein response gene XBP-1 are significantly associated with clinical outcome of endocrine-treated breast cancer.
     Int J Cancer, 123(1): 85-8. [Abstract] [Full-text]

© 2004-2008 Breast Cancer Research Today. All Rights Reserved.